دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Rethinking the MS brain: Synaptic loss and computational modelling of brain networks
Massimiliano Di Filippo Andrea Mancini
doi : 10.1177/13524585221124307
Volume 28 Issue 13, November 2022
Extended dosing of monoclonal antibodies in multiple sclerosis
Zoé LE van Kempen Alyssa A Toorop Finn Sellebjerg Gavin Giovannoni Joep Killestein
Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study
Marijn Huiskamp Svenja Kiljan Shanna Kulik Maarteen E Witte Laura E Jonkman John GJM Bol Geert J Schenk Hanneke E Hulst Prejaas Tewarie Menno M Schoonheim Jeroen JG Geurts
Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis
Dimitrios C Ladakis Pamela J Yao Michael Vreones Joseph Blommer Grigorios Kalaitzidis Elias S Sotirchos Kathryn C Fitzgerald Shiv Saidha Peter A Calabresi Dimitrios Kapogiannis Pavan Bhargava
Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions
Ian J Tagge Ilana R Leppert Dumitru Fetco Jennifer SW Campbell David A Rudko Robert A Brown Nikola Stikov G Bruce Pike Paul S Giacomini Douglas L Arnold Sridar Narayanan
Mechanisms of central brain atrophy in multiple sclerosis
Samuel Klistorner Michael H Barnett Alexander Klistorner
Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study
Christopher C Hemond Jonggyu Baek Carolina Ionete Daniel S Reich
Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study
Laura Cacciaguerra Damiano Mistri Paola Valsasina Vittorio Martinelli Massimo Filippi Maria A Rocca
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
Magnus Johnsson Helen H Farman Kaj Blennow Henrik Zetterberg Clas Malmestr?m Markus Axelsson Jan Lycke
Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels
Carlos Camara-Lemarroy Luanne Metz Jens Kuhle David Leppert Eline Willemse David KB Li Anthony Traboulsee Jamie Greenfield Graziela Cerchiaro Claudia Silva V Wee Yong
doi : 10.1177/13524585221109761
In the trial of Minocycline in Clinically Isolated Syndrome (MinoCIS), minocycline significantly reduced the risk of conversion to clinically definite multiple sclerosis (CDMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers in MS, and minocycline modulates matrix metalloproteinases (MMPs).
Two years’ effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis
Damiano Marastoni, Francesco Crescenzo*, Anna I Pisani, Carmela Zuco,Gianmarco Schiavi, Giulia Benedetti, Giuseppe K Ricciardi, Stefania Montemezzi,Francesca B Pizzini, Agnese Tamanti and Massimiliano Calabrese
doi : 10.1177/13524585221104014
Data on the effect of dimethyl fumarate (DMF) on focal and diffuse gray matter (GM) damage, a relevant pathological substrate of multiple sclerosis (MS)-related disability are lacking.
The impact of bariatric surgery on disease activity and progression of multiple sclerosis: A nationwide matched cohort study
Hedström Anna Karin, Stenberg Erik, Spelman TimForsberg Lars, Näslund Erikand Hillert Jan
doi : 10.1177/13524585221107095
Surgical outcomes in patients with multiple sclerosis (MS) following metabolic surgery appear to be similar compared to those of the general bariatric population.
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
Irene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, Maria Teresa Ferrò,Alice Laroni, Eleonora Cocco, Gaia Cola, Livia Pasquali, Maria Teresa Rilla,Elisabetta Signoriello, Rosa Iodice, Alessia Di Sapio, Roberta Lanzillo, Francesca Caleri,Pietro Annovazzi, Antonella Conte, Giuseppe Liberatore, Francesca Ruscica, Renato Docimo,Simona Bonavita, Monica Ulivelli, Paola Cavalla, Francesco Patti, Diana Ferraro,Marinella Clerico, Paolo Immovilli, Massimiliano Di Filippo, Marco Salvettiand Maria Pia Sormani; the “Breakthrough infections in MS� study group
doi : 10.1177/13524585221102918
Patients with multiple sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to SARS-CoV-2 vaccines.
A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database
Jee-Eun Kim*, Jin Parkand Tae-Jin Song
doi : 10.1177/13524585221109397
Limited information is available on associations between COVID-19 vaccines and central nervous system (CNS) demyelinating diseases.
A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
Stefanos E Prouskas, Menno M Schoonheim, Marijn Huiskamp,Martijn D Steenwijk, Karin Gehring, Frederik Barkhof, Brigit A de Jong,Margriet M Sitskoorn, Jeroen JG Geurts and Hanneke E Hulst
doi : 10.1177/13524585221103134
Cognitive training elicits mild-to-moderate improvements in cognitive functioning in people with multiple sclerosis (PwMS), although response heterogeneity limits overall effectiveness.
Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years
Emilio Portaccio, Luisa Pastò, Lorenzo Razzolini, Lucia Moiola, Vittorio Martinelli,Pietro Annovazzi, Angelo Ghezzi, Mauro Zaffaroni, Roberta Lanzillo,Vincenzo Brescia Morra, Francesca Rinaldi, Paolo Gallo, Claudio GasperiniDamiano Paolicelli, Marta Simone, Carlo Pozzilli, Laura De Giglio, Paola Cavalla,Eleonora Cocco, Maria Giovanna Marrosu, Francesco Patti, Claudio Solaro,Giancarlo Comi, Massimo Filippi, Maria Trojano and Maria Pia Amatofor the MS StudyGroup of the Italian Neurological Society
doi : 10.1177/13524585221079598
To assess the impact of timing of natalizumab cessation/redosing on long-term maternal and infant outcomes in 72 out of the original 74 pregnancies of the Italian Pregnancy Dataset in multiple sclerosis (MS).
Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders
Lorenzo Saraceno, Fiammetta Pirro, Rosa Stigliano, Elio Clemente Agostoniand Alessandra Protti
doi : 10.1177/13524585221125360
In recent years, several disease-modifying therapies have been developed for the treatment of multiple sclerosis (MS). Cladribine transiently depletes B and T lymphocytes, with subsequent gradual cell recovery. No cases are reported in literature describing Cladribine drug-induced liver injury (DILI).
Cladribine-induced liver injury: Implications for practice
Wallace J Brownlee
Tracking the role of sphingolipids in MS: The dynamic nature of ceramide synthases
Thomas Medinaand Saúl Reyes
Response to�Tracking the role of sphingolipids in MS: The dynamic nature of ceramide synthases
Pavan Bhargava, Norman Haugheyand Peter A Calabresi
Anti-CGRP therapies for migraine in multiple sclerosis patients
Alicia Gonzalez-Martinez1, Gauruv Boseand Tanuja Chitnis
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
Klaus Schmierer, Heinz WiendlCelia Oreja-GuevaraDiego Centonze6,7, Anita ChudeckaSanjeev Royand Ursula Boschert
